Consolidating Cancer Care Information in a Single Electronic Database

Commentary
Video

A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.

In a conversation with CancerNetwork®, Leila Tchelebi, MD, a radiation oncologist at Northwell Health, discussed the rationale for assessing the use of a comprehensive cancer database across multiple research and care centers. She spoke in the context of findings that she presented in a poster session at the 2025 American Society for Radiation Oncology Annual Meeting.

Tchelebi described how her research aimed to reduce the time and effort that clinicians usually spend on chasing down information in multiple medical records across several different inpatient and outpatient operations. Using a platform called Oncora, Tchelebi and colleagues demonstrated the feasibility of consolidating data from a variety of disparate electronic medical records (EMRs).

Transcript:

One of the troubles in medicine is that information that can be essential for patient care is distributed amongst different medical records that do not necessarily interface with one another, which results in a lot of extra time and effort for clinicians to chase down the information in the various medical records. This becomes particularly problematic at a large health system such as Northwell, where we have multiple hospitals on the inpatient and the outpatient side, different labs, and different places where patients can get imaging studies done. If you need to collect all the data for an individual patient from these various places, faxes get involved, and [you] have to collect [them]. You cannot always get the records electronically, and it becomes a big mess and a challenge for multiple areas of care, not only the care in the clinic, but as far as research you might want to conduct. The cancer registry collects information on patients that is required to be submitted nationally to state and government registries, so there are many reasons why all of a patient’s relevant medical history needs to be consolidated into 1 easy-to-find place, if possible.

The purpose of this research was to see if it was feasible. There is a database that has been created; it’s called Oncora. [It] collects data from these disparate EMRs. The question was, can we utilize those data in an effective means across our cancer network? That was our goal: to see if it was feasible, to see if this could be done, and if it would be useful. We found that, in fact, it truly is.

The database is available at a particular website that is institution-specific. Northwell has an Oncora interface that we are able to access. There are [several] data elements already there; those get imported into the database, and then you can extract them based on the inquiry that you input. If there are variables that are missing—for example, another research project that we presented at ASTRO required some lab values that were not already existing in the database—we are able to contact the creators of the database, and then they can work with their team to extract those data. Truly, it seems to be limitless as far as what data can be imported. If it is not already there, it can be added.

Reference

Tchelebi L, Lindsay WD, Yee K, Wishinsky J, Labarca ME, Potters L. Building a comprehensive cancer database across fourteen treatment facilities in a large health care system. Presented at: 2025 American Society for Radiation Oncology Annual Meeting; September 27-October 1, 2025; San Francisco, CA.

Recent Videos
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.